Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Puma Biotechnology initiated the Phase II ALISCA-Lung2 trial evaluating alisertib combined with paclitaxel for advanced small cell lung cancer. The clinical-trial start advances the company’s oncology pipeline, but no efficacy, safety, financial, or regulatory results were reported.